How the Moderna/Merck Phase 3 Trial Success Could Transform mRNA Vaccines into Personalized Medicines
Author: Anthony Person, Ph.D. Director of Business Development at CELLSCRIPT™ The recent Phase 3 success of INTerpath-001, the pivotal trial evaluating Moderna and Merck’s personalized cancer vaccine intismeran autogene (mRNA-4157/V940) in combination with Keytruda, may represent one of the most important milestones in the evolution of mRNA technology since the COVID-19 pandemic. The trial demonstrated [...]
